Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cigna GroupCI · Entity 550 | See Remarks | September 01, 2026 | September 03, 2026 |
| TRINET GROUP, INC.TNET · Entity 4202 | Director | May 28, 2026 | June 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cigna Group
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | Direct | 41,030 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 3,113 · Balance 41,030 F1: These restricted shares vest in three equal annual installments beginning September 1, 2027. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $281.13 · Expires 2037-09-01 | Direct | 6,716 |
Reported balance
After 2026-09-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-01 · Grant · Acquired 6,716 · Balance 6,716 F3: This option vests in three equal annual installments beginning September 1, 2027. |
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | IndirectBy GRAT | 25,614 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,614 |
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | IndirectBy 401(k) | 919.5791 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 919.5791 F2: Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted shares vest in three equal annual installments beginning September 1, 2027.
F2: Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.
F3: This option vests in three equal annual installments beginning September 1, 2027.
TRINET GROUP, INC.
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,300 |
Reported balance
After 2026-05-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 4,735 · Balance 14,300 F1: Reflects the grant of Restricted Stock Units that convert into Common Stock, par value $0.000025 per share, of the Issuer, on a one-for-one basis. The Restricted Stock Units will vest 100% on the earlier of the 12-month anniversary of the date of grant and the trading day preceding the date of the Company's 2027 Annual Meeting of the Stockholders, subject to the director's continued service. The Restricted Stock Units are also subject to accelerated vesting upon certain events. F2: The total securities beneficially owned includes shares of unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of Restricted Stock Units that convert into Common Stock, par value $0.000025 per share, of the Issuer, on a one-for-one basis. The Restricted Stock Units will vest 100% on the earlier of the 12-month anniversary of the date of grant and the trading day preceding the date of the Company's 2027 Annual Meeting of the Stockholders, subject to the director's continued service. The Restricted Stock Units are also subject to accelerated vesting upon certain events.
F2: The total securities beneficially owned includes shares of unvested restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cigna Holding Co
Report date December 20, 2018 · Filed December 26, 2018
Section 16 reporting ended · disclosed 2018-12-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.25 Par ValueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 1
1 source rowRow 1 · 2018-12-20 · Disposition to issuer · Disposed 3,841 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. |
| Common Stock, $.25 Par ValueSEC Table I · non-derivative | IndirectBy 401(k) | 0 |
Reported balance
After 2018-12-20 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-12-20 · Disposition to issuer · Disposed 832.0542 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F8: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.04 · Expires 2024-02-26 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-20 · Disposition to issuer · Disposed 2,877 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.90 · Expires 2025-02-25 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-12-20 · Disposition to issuer · Disposed 5,806 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.22 · Expires 2026-03-01 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-12-20 · Disposition to issuer · Disposed 6,269 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F5: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.14 · Expires 2027-02-28 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-12-20 · Disposition to issuer · Disposed 5,849 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F6: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $197.35 · Expires 2028-02-28 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-12-20 · Disposition to issuer · Disposed 6,311 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F7: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote)
F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.
F3: This option was fully vested and exercisable at the time of the Merger.
F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option.
F5: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.
F6: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.
F7: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms.
F8: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 20:21 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 6,716 | $0.00 Strike: $281.13 | $0.00 |
DisclosureSEC source: 0001722909-26-000007 · wk-form4_1788466902.xml · derivative · entry 4 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,716 Underlying: Common Stock, $0.01 Par Value · 6,716 shares Expires 2037-09-01 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning September 1, 2027. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:21 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 3,113 | $0.00 | $0.00 |
DisclosureSEC source: 0001722909-26-000007 · wk-form4_1788466902.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,030 F1 · shares: These restricted shares vest in three equal annual installments beginning September 1, 2027. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 22:09 UTC | TRINET GROUP, INC. TNET · Entity 4202 | GrantCommon Stock | 4,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001722909-26-000005 · wk-form4_1780351743.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,300 F1 · shares: Reflects the grant of Restricted Stock Units that convert into Common Stock, par value $0.000025 per share, of the Issuer, on a one-for-one basis. The Restricted Stock Units will vest 100% on the earlier of the 12-month anniversary of the date of grant and the trading day preceding the date of the Company's 2027 Annual Meeting of the Stockholders, subject to the director's continued service. The Restricted Stock Units are also subject to accelerated vesting upon certain events. F2 · balance_after: The total securities beneficially owned includes shares of unvested restricted stock units. Read SEC document |
| March 04, 2026 Filed May 18, 2026 22:50 UTC | TRINET GROUP, INC. TNET · Entity 4202 | PurchaseCommon Stock | 5,000 | $37.70 | $188,500.00 |
DisclosureSEC source: 0001722909-26-000003 · wk-form4_1779144600.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,565 F1 · kind: Due to an administrative oversight, a required Form 4 for this transaction was not filed on a timely basis. The reporting person is filing this Form 4 promptly after becoming aware of the omission. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:17 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,082 | $0.00 Strike: $287.55 | $0.00 |
DisclosureSEC source: 0001739940-26-000012 · wk-form4_1772583425.xml · derivative · entry 7 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,082 Underlying: Common Stock, $.01 Par Value · 15,082 shares Expires 2036-02-27 F7 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2027. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:17 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 1,788 | $287.55 | $514,139.40 |
DisclosureSEC source: 0001739940-26-000012 · wk-form4_1772583425.xml · nonDerivative · entry 4 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,917 F4 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:17 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 2,979 | $287.55 | $856,611.45 |
DisclosureSEC source: 0001739940-26-000012 · wk-form4_1772583425.xml · nonDerivative · entry 3 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,705 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:17 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 9,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001739940-26-000012 · wk-form4_1772583425.xml · nonDerivative · entry 2 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,684 F2 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2027. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:17 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 6,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001739940-26-000012 · wk-form4_1772583425.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,897 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2023-2025 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| October 06, 2025 Filed Oct 7, 2025 21:22 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 901 | $0.00 Strike: $139.22 | $0.00 |
DisclosureSEC source: 0001739940-25-000032 · wk-form4_1759872170.xml · derivative · entry 6 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.01 Par Value · 901 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2025. F3 · derivative.exercise_date: This option was granted on March 1, 2016. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| October 06, 2025 Filed Oct 7, 2025 21:22 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 901 | $139.22 | $125,437.22 |
DisclosureSEC source: 0001739940-25-000032 · wk-form4_1759872170.xml · nonDerivative · entry 3 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2025. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:22 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,368 | $0.00 Strike: $139.22 | $0.00 |
DisclosureSEC source: 0001739940-25-000032 · wk-form4_1759872170.xml · derivative · entry 5 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 901 Underlying: Common Stock, $0.01 Par Value · 5,368 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2025. F3 · derivative.exercise_date: This option was granted on March 1, 2016. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:22 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 5,368 | $300.00 | $1,610,400.00 |
DisclosureSEC source: 0001739940-25-000032 · wk-form4_1759872170.xml · nonDerivative · entry 2 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,182 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2025. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:22 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 5,368 | $139.22 | $747,332.96 |
DisclosureSEC source: 0001739940-25-000032 · wk-form4_1759872170.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2025. Read SEC document |
| May 23, 2025 Filed May 28, 2025 22:46 UTC | TRINET GROUP, INC. TNET · Entity 4202 | GrantCommon Stock | 2,649 | $0.00 | $0.00 |
DisclosureSEC source: 0000937098-25-000115 · wk-form4_1748472354.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,565 F1 · shares: Reflects the grant of Restricted Stock Units that convert into Common Stock, par value $0.000025 per share, of the Issuer, on a one-for-one basis. The Restricted Stock Units will vest 100% on the earlier of the 12-month anniversary of the date of grant and the trading day preceding the date of the Company's 2025 Annual Meeting of the Stockholders, subject to the director's continued service. The Restricted Stock Units are also subject to accelerated vesting upon certain events. F2 · balance_after: The total securities beneficially owned includes shares of unvested restricted stock units. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:52 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 19,158 | $0.00 Strike: $305.86 | $0.00 |
DisclosureSEC source: 0001225208-25-002924 · doc4.xml · derivative · entry 6 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,158 Underlying: Common Stock, $.01 Par Value · 19,158 shares Expires 2035-02-28 F6 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2026. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:52 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 5,679 | $305.86 | $1,736,978.94 |
DisclosureSEC source: 0001225208-25-002924 · doc4.xml · nonDerivative · entry 4 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,182 F4 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:52 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 1,722 | $305.86 | $526,690.92 |
DisclosureSEC source: 0001225208-25-002924 · doc4.xml · nonDerivative · entry 3 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,861 F3 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:52 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 5,395 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-002924 · doc4.xml · nonDerivative · entry 2 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,583 F2 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2026. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:52 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 12,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-002924 · doc4.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,188 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2022-2024 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 22:09 UTC | TRINET GROUP, INC. TNET · Entity 4202 | GrantCommon Stock | 1,916 | $0.00 | $0.00 |
DisclosureSEC source: 0000937098-24-000140 · wk-form4_1720649378.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,916 F1 · shares: Reflects the grant of Restricted Stock Units that convert into Common Stock, par value $0.000025 per share, of the Issuer, on a one-for-one basis. The Restricted Stock Units will vest 100% on the earlier of the 12-month anniversary of the date of grant and the trading day preceding the date of the Company's 2025 Annual Meeting of the Stockholders, subject to the director's continued service. The Restricted Stock Units are also subject to accelerated vesting upon certain events. F2 · balance_after: The total securities beneficially owned includes shares of unvested restricted stock units. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 21:07 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,011 | $0.00 Strike: $120.90 | $0.00 |
DisclosureSEC source: 0001225208-24-007005 · doc4.xml · derivative · entry 6 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 1,011 shares Expires 2025-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. F4 · derivative.exercise_date: This option was granted on February 25, 2015. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 21:07 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 1,011 | $120.90 | $122,224.85 |
DisclosureSEC source: 0001225208-24-007005 · doc4.xml · nonDerivative · entry 3 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 21:07 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,795 | $0.00 Strike: $120.90 | $0.00 |
DisclosureSEC source: 0001225208-24-007005 · doc4.xml · derivative · entry 5 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,011 Underlying: Common Stock, $.01 Par Value · 4,795 shares Expires 2025-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. F4 · derivative.exercise_date: This option was granted on February 25, 2015. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 21:07 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 4,795 | $345.01 | $1,654,302.81 |
DisclosureSEC source: 0001225208-24-007005 · doc4.xml · nonDerivative · entry 2 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,923 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $345.00 to $345.07 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 21:07 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 4,795 | $120.90 | $579,691.53 |
DisclosureSEC source: 0001225208-24-007005 · doc4.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:43 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 3,860 | $333.36 | $1,286,769.60 |
DisclosureSEC source: 0001225208-24-003709 · doc4.xml · nonDerivative · entry 3 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,923 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:43 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 1,575 | $333.36 | $525,042.00 |
DisclosureSEC source: 0001225208-24-003709 · doc4.xml · nonDerivative · entry 2 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,783 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:43 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 8,329 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-003709 · doc4.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,358 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2021-2023 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 00:44 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,677 | $0.00 Strike: $336.48 | $0.00 |
DisclosureSEC source: 0001225208-24-003416 · doc4.xml · derivative · entry 3 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,677 Underlying: Common Stock, $.01 Par Value · 18,677 shares Expires 2034-02-28 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2025. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 00:44 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 5,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-003416 · doc4.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,029 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2025. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 21:21 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 570 | $0.00 Strike: $78.04 | $0.00 |
DisclosureSEC source: 0001225208-23-008003 · doc4.xml · derivative · entry 6 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 570 shares Expires 2024-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2023. F3 · derivative.exercise_date: This option was granted on February 26, 2014. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 21:21 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 570 | $78.04 | $44,479.95 |
DisclosureSEC source: 0001225208-23-008003 · doc4.xml · nonDerivative · entry 3 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2023. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 21:21 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,307 | $0.00 Strike: $78.04 | $0.00 |
DisclosureSEC source: 0001225208-23-008003 · doc4.xml · derivative · entry 5 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 570 Underlying: Common Stock, $.01 Par Value · 2,307 shares Expires 2024-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2023. F3 · derivative.exercise_date: This option was granted on February 26, 2014. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 21:21 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 2,307 | $300.00 | $692,100.00 |
DisclosureSEC source: 0001225208-23-008003 · doc4.xml · nonDerivative · entry 2 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,332 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2023. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 21:21 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 2,307 | $78.04 | $180,026.75 |
DisclosureSEC source: 0001225208-23-008003 · doc4.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:11 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 1,342 | $289.44 | $388,428.48 |
DisclosureSEC source: 0001225208-23-003381 · doc4.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,332 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 23:01 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 2,792 | $294.27 | $821,601.84 |
DisclosureSEC source: 0001225208-23-002991 · doc4.xml · nonDerivative · entry 3 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,674 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 23:01 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 348 | $294.27 | $102,405.96 |
DisclosureSEC source: 0001225208-23-002991 · doc4.xml · nonDerivative · entry 2 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,466 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 23:01 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 6,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002991 · doc4.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,814 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2020-2022 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:12 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 16,268 | $0.00 Strike: $294.61 | $0.00 |
DisclosureSEC source: 0001225208-23-002823 · doc4.xml · derivative · entry 3 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,268 Underlying: Common Stock, $.01 Par Value · 16,268 shares Expires 2033-02-22 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2024. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:12 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 4,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002823 · doc4.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,055 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2024. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 22:28 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 607 | $236.48 | $143,543.36 |
DisclosureSEC source: 0001225208-22-004170 · doc4.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,652 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 25, 2022 Filed Mar 2, 2022 01:18 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 767 | $229.64 | $176,133.88 |
DisclosureSEC source: 0001225208-22-003749 · doc4.xml · nonDerivative · entry 3 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,259 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document |
| February 25, 2022 Filed Mar 2, 2022 01:18 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 599 | $229.64 | $137,554.36 |
DisclosureSEC source: 0001225208-22-003749 · doc4.xml · nonDerivative · entry 2 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,026 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 25, 2022 Filed Mar 2, 2022 01:18 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 2,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003749 · doc4.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,625 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2019-2021 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 01:48 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 21,297 | $0.00 Strike: $227.02 | $0.00 |
DisclosureSEC source: 0001225208-22-003484 · doc4.xml · derivative · entry 3 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,297 Underlying: Common Stock, $.01 Par Value · 21,297 shares Expires 2032-02-23 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 01:48 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003484 · doc4.xml · nonDerivative · entry 1 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,178 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2023. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 644 | $210.31 | $135,439.64 |
DisclosureSEC source: 0001225208-21-004363 · doc4.xml · nonDerivative · entry 3 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,428 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 601 | $210.31 | $126,396.31 |
DisclosureSEC source: 0001225208-21-004363 · doc4.xml · nonDerivative · entry 2 Evanko Brian C · CIK 0001722909 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,072 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.